European Parliament President Commends UAE’s Tolerance Model, Role as Supporter of International Stability and Security
His Excellency Antonio Tajani, President of the European Parliament, stressed the importance of joint efforts to ensure security and stability in the Middle East during a meeting with Her Excellency Dr Amal Al Qubaisi, Speaker of the UAE Federal National Council (FNC), on January 9 at the headquarters of the European Parliament in Brussels.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190110005589/en/
His Excellency Antonio Tajani, President of the European Parliament, and Her Excellency Dr Amal Al Qubaisi, Speaker of the UAE Federal National Council (FNC) (Photo: AETOSWire)
Commending the developing relations between the UAE and the EU, His Excellency Antonio Tajani praised the UAE’s approach of promoting tolerance and empowering women and youth, and appreciated the UAE’s declaration of 2019 as the Year of Tolerance. He also highlighted FNC’s role in driving international parliamentary efforts to counter terrorism and extremism.
The two dignitaries discussed ways to enhance relations between the UAE and EU countries. They emphasized the importance of collective commitment among the world’s nations to avoid instigating sectarian tensions and supporting terrorist militias, as well as joint efforts to combat terrorism and extremism and eliminate sources of funding for extremist ideologies.
Pointing out the importance of the exhibition organized by the Emirates Red Crescent at the European Parliament’s headquarters, His Excellency Antonio Tajani said: “The exhibition introduces Europeans to the humanitarian efforts of the UAE. The country has become a global model for promoting peace and stability through its humanitarian role in Yemen and its assistance to victims of disasters and crises as the largest international aid donor relative to GDP.”
Her Excellency Dr Al Qubaisi said: “The UAE is keen to strengthen synergies with the European Parliament in view of our common vision on various issues, notably the aspirations for a secure and stable future for the world. The country has provided humanitarian assistance to more than 100 nations, having dispensed aid worth over US$32 billion from 2013 to 2017.”
She also discussed the UAE’s position on the legitimate restoration of its three islands occupied by Iran through direct official negotiations or recourse to the International Court of Justice. Furthermore, she called on the EU to leverage its strong relations with relevant countries to reach peaceful resolutions to crises around the world, and to urge Iran to stop undermining the stability of the region through sponsoring terrorism.
Federal National Council, United Arab Emirates:
Mohammed Al-Sawafi, +971506183874
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Rimini Street CEO Visits Seoul, Addresses Changing IT Mission19.3.2019 23:00:00 CET | Pressemelding
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, is committed to helping South Korean companies reduce ongoing IT operating costs and freeing up significant IT budget to invest in innovation, competitive advantage and growth, co-founder and CEO Seth A. Ravin explained during a press conference in Seoul. Mr. Ravin also highlighted continued strong and growing demand in Korea for the Company’s award-winning, ultra-responsive enterprise software support model, which is disrupting the $160 billion enterprise software maintenance market worldwide. As the 4th largest economy in Asia, and the 11th largest in the world, South Korea represents a large market opportunity for the Company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190319005832/en/ Rimini Street CEO Visits Seoul,
SOTIO’s DCVAC/OvCa Significantly Improves Survival in Patients with Recurrent Ovarian Cancer19.3.2019 20:00:00 CET | Pressemelding
SOTIO, a biotechnology company owned by the PPF Group, presented results from SOV02, its Phase II clinical trial evaluating DCVAC/OvCa, an active cellular immunotherapy product, in patients with recurrent ovarian cancer at 2019 SGO’s 50 th Annual Meeting on Women's Cancer today. Final analysis of SOV02 shows that DCVAC/OvCa decreased the risk of death significantly compared to patients who did not receive DCVAC/OvCa. Clinical trial results were presented during today’s SGO 2019 Plenary Session by SOV02 principal investigator David Cibula, MD, PhD from General University Hospital in Prague (Czech Republic). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190319005837/en/ In the randomized, open label SOV02 clinical trial, patients with recurrent ovarian cancer received DCVAC/OvCa in combination with platinum-based chemotherapy. Compared to patients who did not receive DCVAC, it decreased the risk of death by 62%. The combinati
OCP Announces Date of Fourth Quarter and Full Year 2018 Earnings19.3.2019 19:00:00 CET | Pressemelding
OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its fourth quarter and full year 2018 results on Monday, March 25, 2019. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 9:00 a.m. EDT, 2:00 p.m. Morocco time (GMT+1), and 1:00 p.m. London time (GMT). OCP senior management will host a conference call to discuss fourth quarter and full year 2018 results at 10:00 a.m. EDT, 3:00 p.m. Morocco time (GMT+1), and 2:00 p.m. London time (GMT) on Monday, March 25, 2019 for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing firstname.lastname@example.org About OCP OCP is a global leader in the fertilizer industry, backed by almost a century’s
HCL and Xerox Expand Strategic Partnership to Accelerate Operational Transformation19.3.2019 16:51:00 CET | Pressemelding
HCL Technologies (HCL), a leading global technology company, announced that it signed a managed services agreement with Xerox (NYSE: XRX). Under the terms of the agreement, HCL will manage portions of Xerox’s shared services, including global administrative and support functions, including, among others, selected information technology and finance functions (excluding accounting). Leveraging HCL’s global scale and capabilities, Xerox will strategically evolve its shared services into process-first, technology-led digital operations. This seven-year agreement for an incremental $1.3 billion continues to build on the success of the Xerox-HCL relationship, which began in 2009 with product engineering and support services. Under that agreement, HCL currently manages aspects of Xerox’s mechanical, electrical and software engineering activities for printer and imaging product lines. Together, HCL and Xerox have delivered 215 U.S. patents and have created world-class R&D labs that are tightly
Abzena and Lipum AB Sign Integrated CMC Agreement to Produce a Novel Biologic for Autoimmune Inflammatory Diseases19.3.2019 15:18:00 CET | Pressemelding
Abzena, the global biologics gene to GMP partner research organization, announced it has signed an agreement to support an integrated CMC program with Lipum, a company developing treatments for chronic inflammatory diseases. Abzena will support Lipum’s anti-BSSL antibody IND program to help develop a novel therapeutic option for autoimmune inflammatory diseases, including juvenile idiopathic arthritis. The 18-month program includes: development of a research cell bank using Abzena’s proprietary cell line and ambr® 15 automated high throughput bioreactors, generation of master cell banks, scale up using an ambr® 250 during process development, followed by cGMP manufacturing in Sartorius 500 L single use stirred tank bioreactors for clinical material. The work will take place at Abzena’s sites in Cambridge, UK and San Diego, USA. Jonathan Goldman, CEO of Abzena, said: “Autoimmune inflammatory diseases such as juvenile idiopathic arthritis represent significant unmet medical need. We are